Leading Financial Service Provider in India | Canara Bank Securities Ltd

Fredun Pharmaceuticals Ltd.

Jun 06 BSE 728.95 ( -1.65 -0.23%)

Volume15965

Prev. Close
730.60

Open Price
736.00

Today's Low / High

721.00 739.80

Bid. Price (Qty.)0.00 (0)

Offer Price (Qty.)
0.00 (0)

52 Wk Low / High

635.00 955.50

Fredun Pharmaceuticals Ltd.is not traded in NSE

Market Cap. ( ₹ in Cr. )	344.19	P/BV	2.63	Book Value ( ₹ )	277.17
52 Week High/Low ( ₹ )	956/635	FV/ML	10/1	P/E(X)	16.54
Book Closure	30/09/2024	EPS ( ₹ )	44.07	Div Yield (%)	0.10

Standalone

(₹ in Crs.)

Particulars	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24
Net Sales/Income from operations	165.44	101.84	106.89	77.54	117.21
Other Operating Income	0.00	0.00	0.00	0.00	0.82
Total Income From Operations	165.44	101.84	106.89	77.54	118.03

EXPENDITURE
Consumption of Raw Materials	125.01	72.66	67.40	57.88	91.82
Increase/Decrease in Stocks	-1.23	-0.26	7.87	-0.33	-1.90
Employees Cost	9.70	5.85	3.58	3.10	3.90
Depreciation	1.25	1.09	1.06	1.05	0.96
Other Expenses	16.49	11.22	14.55	7.68	13.05
Total Expenses	151.22	90.56	94.47	69.38	107.82

P/L Before Other Inc. , Int., Excpt. Items & Tax	14.22	11.28	12.43	8.16	10.21
Other Income	1.97	0.86	0.46	1.28	0.00
P/L Before Interest, Excpt. Items & Tax	16.19	12.14	12.89	9.43	10.21
Interest	8.15	5.00	5.31	3.91	4.37
P/L Before Exceptional Items & Tax	8.04	7.13	7.58	5.52	5.84
P/L Before Tax	8.04	7.13	7.58	5.52	5.84
Tax	0.97	1.80	3.30	1.39	0.78
P/L After Tax from Ordinary Activities	7.07	5.33	4.27	4.13	5.06
Net Profit/Loss For the Period	7.07	5.33	4.27	4.13	5.06

Equity Share Capital	4.72	4.72	4.72	4.70	4.70
EPS Before Extra Ordinary *
Basic EPS (Rs.)	14.98	11.29	9.05	8.79	10.77
Diluted EPS (Rs.)	14.98	11.29	9.05	8.79	10.77
EPS After Extra Ordinary *
Basic EPS (Rs.)	14.98	11.29	9.05	8.79	10.77
Diluted EPS (Rs.)	14.98	11.29	9.05	8.79	10.77

PBITOE Margin (%)	8.59	11.07	11.62	10.51	8.65
PBTE Margin (%)	4.86	7.00	7.08	7.11	4.94
PBT Margin (%)	4.86	7.00	7.08	7.11	4.94
PAT Margin (%)	4.27	5.23	3.99	5.32	4.28

Markets

Quarterly Results

QUARTERLY RESULTS

Fredun Pharmaceuticals Ltd.